close
Respiratory Diagnostics
Respiratory Diagnostics

Diagnose, monitor and manage patients’ respiratory health in the most efficient and effective way possible.

Technical Support
Product Registration
Devices
Spirometry Pulmonary Function Testing Respiratory Muscle Strength Complementary Diagnostics Respiratory Monitoring & Screening Bacterial Viral Filters
Solutions
V-Core Flowhead Technology VitaloPFT Office Diagnostics Clinic Diagnostics Hospital Diagnostics
Clinical Trials
Clinical Trials

Custom solutions and a personalized approach mean we can meet a wide range of respiratory clinical study needs.

Clinical Trial Services
Case Studies
Expertise
Respiratory Expertise Cough Studies Asthma studies COPD studies Cystic fibrosis studies Rare disease studies Interstitial lung disease
Solutions
Clinical Endpoint Solutions Respiratory in-clinic Cough monitoring Home monitoring Study centralization Cardiac safety
Resources
Training
On-demand devices & software training Tailored device & software training Spirometry workshops
Education
Respiratory Insights Clinical Trial Insights Webinars
Clinical Library
Reference Papers Clinical Practice Guidelines Whitepapers Lung Function Reference Values
News & Insights
Vital Insights

The latest respiratory news including clinical research, articles on respiratory topics, patient information pieces, and episodes of our ever popular Exhale podcast.

Insights
Respiratory Insights Clinical Trial Insights Exhale Podcast At Vitalograph
News & Events
News Events
About
About

Vitalograph products and services are chosen by medical professionals in over 113 countries for healthcare, occupational health, and clinical trials.

Company Careers Sustainability At Vitalograph
Contact
contact_support
menu
Contact

COVID-19 Virus: Vitalograph Statement

Message from our CEO Frank Keane

Due to the ongoing global impact of the COVID-19 (SARS-CoV-2) virus situation, we continue to monitor the effect this may have on our business worldwide.

Vitalograph’s manufacturing site is based in Ireland and has experienced little or no disruption to output during the pandemic. Like most global companies, some of our constituent components are sourced in the Far-East and whilst there was some supply disruption in early 2020, this has since stabilized, and we are currently not experiencing any supply chain issues.

As a global company, we have warehouses in multiple countries holding adequate levels of stock to meet current, and anticipated, customer needs. We also have a wide range of products allowing a supply of alternative items should short term stock issues arise. We are seeing an ongoing manageable slowing of 1-2 days on outgoing logistics in Europe.

Recently, further travel restrictions have been imposed across Europe and we expect further measures to be imposed in North and South America. We are prepared for this and our ongoing Business Continuity Plan (BCP) measures, invoked at all sites in the middle of February, include remote working, staggered breaks and dispersed workforce. We practice a robust BCP process, aligned to ISO 22301, tested regularly at all sites. None of our sites has had to close to date.

We welcome the recent news of successful vaccine trials, and wish those companies developing vaccines well in their efforts but are mindful of the unprecedented manufacturing and logistical challenges remaining before these vaccines are widely available. We will continue to practice our mitigation measures until such time as the Covid-19 threat has greatly receded.

Our Company Mission is “To improve patient lives through supporting our customers and partners by designing and manufacturing market leading products and services”. This is a mission we take very seriously, and our employees live and breathe it on a daily basis. Due to the respiratory effects of COVID-19 we are doubling our efforts to ensure we can fulfil our mission and help those in most need at this time.

Regards

Frank Keane Signature

Frank Keane CEO

Contact Us